INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Ambrose Kristen reported VRTX

SVP & Chief Accounting Officer · VERTEX PHARMACEUTICALS INC / MA · Common Stock

Side
A
Value
—
Shares
2,950
Price
—
Executed
Jan 22, 2026
Disclosed
Jan 26, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 22 executedJan 26, 2026 disclosed

VRTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 37.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VRTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    David J. TaylorRSelf
    VRTXVERTEX PHARMACEUTICALS INC / MA
    Sale
    		SELL$1,001 – $15KAug 26, 2026Sep 5, 2026
    traded Aug 26, 2026
    		+10dHOUSE PTR

    Evidence

    13
    AK
    Ambrose KristenSVP & Chief Accounting Officer
    VRTXVERTEX PHARMACEUTICALS INC / MA
    Grant or award
    		A—
    1,300 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001856587-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 22, 2026
    Published
    Jan 26, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Ambrose Kristen
    Role
    SVP & Chief Accounting Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    VERTEX PHARMACEUTICALS INC / MA
    Ticker
    VRTX
    Shares
    2,950
    Price per share
    $0
    Execution date (reported)
    Jan 22, 2026
    Owned after transaction
    10.8K shares
    Days from execution to publication
    4

    What this establishes

    Ambrose Kristen filed this Form 4 reporting a grant or award of VRTX on Jan 22, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP & Chief Accounting Officer
    Ambrose Kristencik:0001856587
    Issuer
    VERTEX PHARMACEUTICALS INC / MAcik:0000875320

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.